We are excited to announce the official start of the development of the SQUEEZE Care Model!!

This marks the beginning of a collaborative journey to create a tailored intervention aimed at improving patient care, with a special focus on medication adherence for people receiving DMARDs (disease-modifying anti-rheumatic drugs).

Built on a Strong Foundation

This first development phase builds on two years of extensive research, including:

  • Contextual analysis across multiple European countries and Switzerland
  • In-depth interviews with key opinion leaders in rheumatology and healthcare
  • Active engagement with stakeholders from across the healthcare ecosystem
  • A Co-Creation Approach

The SQUEEZE Care Model will be developed using a co-creation strategy. This means the intervention will be shaped collaboratively with key stakeholders, including patients, clinicians, researchers, and health system experts. Their diverse perspectives and experiences will help ensure the solution is both practical and meaningful in real-world settings.

Partners Making It Possible

This milestone would not be possible without the dedicated efforts of our consortium members and collaborators:

  • University of Basel, Switzerland
  • Rheuma Basel Praxis, Switzerland
  • University Hospital Basel, Switzerland
  • INMUSC, Spain
  • HealthBuddy, Denmark

And, of course, our invaluable Patient Research Partners

Ensuring Quality Through Continuous Feedback

To ensure the intervention is evidence-based and feasible, the development process will be supported by:

  • Experts in implementation science
  • Advisory panels composed of clinicians and patients
  • Trial teams from two clinical centres
  • On-demand consultants, including health economists, IT experts, and policy advisors

Looking Ahead

We are thrilled to take this first step in the development of the SQUEEZE Care Model and look forward to sharing further updates as we progress. Together, we are laying the foundation for innovative, patient-centred care in rheumatology.

Stay tuned—and thank you for being part of the journey!!

Share This Story, Choose Your Platform!